Create health, happy lives and beautiful future

EDGC is at the center of the revolution beginning to disappear a border between industries as technologies converge.

Help to maintain healthy pregnancy by analyzing fetal chromosomal abnormalities.
Detect chromosomal abnormalities a baby may have.
Parents can take care of children’s health with proper treatment of analyzing their genes.
Analyze the genetic risk of diseases to help prevent them in advance.

Genetic Analysis Service Throughout the Life Cycle

What does
your DNA look like?

MIT Technology Review paid attention to
‘Genetic Fortune Telling’ in ’10 Breakthrough Technologies 2018’.
Genes have all the information you may wish to know.
Your genes exactly know your weaknesses, personality, aptitude and even the most effective exercises for you.
Start to prepare for the era of the healthy 100-year life through genetic analysis.
EDGC is
a global healthcare
company.

EDGC analyzes your genes based on
cutting-edge genetic analysis technology and bioinformatics technology and suggests personalized lifestyle to help prevent diseases.

Business

EDGC Service

Non-Invasive Prenatal Test
NICE®

NICE® test, which has been verified its accuracy and reliability by acquiring CLIA and CAP certificates, detects fetal chromosomal abnormalities safely and easily.
Newborn Genetic Screening Test
bebegene®

bebegene® which detects chromosomal abnormalities such as major genetic diseases, Wilson’s Disease, ADHD, hearing loss and so on is the first test for a precious baby.
Integrated Genotype and Phenotype Test
MYGENPLAN®

MYGENPLAN® is the first integrated test in South Korea which analyzes metabolic genes and biological age and suggests personalized healthcare guide.
Cancer and General Disease Prediction Test
gene2me® Plus

gene2me® Plus predicts the genetic risk of major cancer, general diseases and eye diseases, and designs healthy future with early personalized treatment.

Recent News

EDGC Recent News

Article

First quarter surplus in just eight year…

First quarter surplus in just eight years. After merging affiliates in the second half of the year, the company will begin to improve its performance. Global genetic company Iwon DIAGNOMIX Co., Ltd. (EDGC) announced on the 14th that it had turned into a surplus for the first time in eight years since its foundation. EDGC said that the performance improvement will be more in full swing in the second half of the year when the merger with EDGC Healthcare is completed. Based on the world's best Cell-free DNA innovation technology, EDGC is upgrading liquid biopsy such as early cancer screening and co-diagnosis, and provides next-generation sequencing NGS analysis-based fetuses, next-generation world-class products that check the health of newborn babies, Nice, Bevezine, and Genetic Disease Prediction tests in 20 countries. Recently, it announced that it will contribute to realizing national precision medical services based on genetic big data by forming "K-DNA 5 Consortium" that represents genetic companies in national bio-big data construction projects. Meanwhile, EDGC newly appointed Lee Myung-hee, CEO of its subsidiary EDGC Healthcare, as co-representative of Solgent and announced that it will maximize strategic cooperation and synergy between EDGC and Solgent under the system of co-representatives Yoo Jae-hyung and Lee Myung-hee.

2020.08.14